These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34345508)

  • 1. Fundamental Measurement: The Need Fulfilment Quality of Life (N-QOL) Measure.
    Langley PC; McKenna SP
    Innov Pharm; 2021; 12(2):. PubMed ID: 34345508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement, modeling and QALYs.
    Langley PC; McKenna SP
    F1000Res; 2020; 9():1048. PubMed ID: 33093950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-Menopausal Quality of Life Claims: Overlooking the Requirements of Normal Science and Fundamental Measurement in ICER'S Cost-Effectiveness Assessment of Fezolinetant for Moderate to Severe Vasomotor Symptoms.
    Langley PC
    Innov Pharm; 2023; 14(1):. PubMed ID: 38035319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonsense on Stilts - Part 1: The ICER 2020-2023 Value Assessment Framework for Constructing Imaginary Worlds.
    Langley PC
    Innov Pharm; 2020; 11(1):. PubMed ID: 34017624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER).
    Langley PC
    Innov Pharm; 2020; 11(3):. PubMed ID: 34007634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping Impossible Utilities: The ICER Report on Tezepelumab for Severe Asthma.
    Langley PC
    Innov Pharm; 2022; 13(2):. PubMed ID: 36654713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis.
    Langley PC
    Innov Pharm; 2021; 12(4):. PubMed ID: 36033123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review's Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis.
    Langley PC
    Innov Pharm; 2020; 11(1):. PubMed ID: 34017631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Problems and solutions in calculating quality-adjusted life years (QALYs).
    Prieto L; Sacristán JA
    Health Qual Life Outcomes; 2003 Dec; 1():80. PubMed ID: 14687421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concerns with Patient Reported Outcome Measurement and Value Claims for Therapy Response: The Case of Mavacamten and Symptomatic Hypertrophic Cardiomyopathy (SHCM).
    Langley PC
    Innov Pharm; 2022; 13(2):. PubMed ID: 36654699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accounts from developers of generic health state utility instruments explain why they produce different QALYs: A qualitative study.
    Pickles K; Lancsar E; Seymour J; Parkin D; Donaldson C; Carter SM
    Soc Sci Med; 2019 Nov; 240():112560. PubMed ID: 31563007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of health-utility data for osteoarthritis: implications for clinical trial-based evaluation.
    Ruchlin HS; Insinga RP
    Pharmacoeconomics; 2008; 26(11):925-35. PubMed ID: 18850762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health state values from multiattribute utility instruments need correction.
    Nord E
    Ann Med; 2001 Jul; 33(5):371-4. PubMed ID: 11491196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing and explaining differences in the magnitude, content, and sensitivity of utilities predicted by the EQ-5D, SF-6D, HUI 3, 15D, QWB, and AQoL-8D multiattribute utility instruments.
    Richardson J; Khan MA; Iezzi A; Maxwell A
    Med Decis Making; 2015 Apr; 35(3):276-91. PubMed ID: 25159172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EQ-5D-5L and SF-6D Utility Measures in Symptomatic benign Thyroid Nodules: Acceptability and Psychometric Evaluation.
    Wong CKH; Lang BHH; Yu HMS; Lam CLK
    Patient; 2017 Aug; 10(4):447-454. PubMed ID: 28224296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
    Yang F; Devlin N; Luo N
    Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health related quality of life aspects not captured by EQ-5D-5L: Results from an international survey of patients.
    Efthymiadou O; Mossman J; Kanavos P
    Health Policy; 2019 Feb; 123(2):159-165. PubMed ID: 30598239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using EQ-5D to derive general population-based utilities for the quality of life assessment of growth hormone deficiency in adults (QoL-AGHDA).
    Kołtowska-Häggström M; Jonsson B; Isacson D; Bingefors K
    Value Health; 2007; 10(1):73-81. PubMed ID: 17261118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiattribute health utility scoring for the computerized adaptive measure CAT-5D-QOL was developed and validated.
    Kopec JA; Sayre EC; Rogers P; Davis AM; Badley EM; Anis AH; Abrahamowicz M; Russell L; Rahman MM; Esdaile JM
    J Clin Epidemiol; 2015 Oct; 68(10):1213-20.e1-6. PubMed ID: 25990544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.